[{"id":"6f7bf383-609e-4543-baf3-bf987cf68486","acronym":"","url":"https://clinicaltrials.gov/study/NCT03728335","created_at":"2023-11-24T19:04:58.043Z","updated_at":"2025-02-25T14:40:02.257Z","phase":"Phase 2","brief_title":"Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation","source_id_and_acronym":"NCT03728335","lead_sponsor":"City of Hope Medical Center","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 01/11/2027","primary_completion_date":" 01/11/2027","study_txt":" Completion: 01/11/2027","study_completion_date":" 01/11/2027","last_update_posted":"2025-02-14"},{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"d6b5f034-4f23-41ab-9424-0eeb245d22d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04203316","created_at":"2021-01-18T20:28:43.981Z","updated_at":"2025-02-25T15:11:26.261Z","phase":"Phase 2","brief_title":"Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation","source_id_and_acronym":"NCT04203316","lead_sponsor":"Children's Oncology Group","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-13"},{"id":"35a86a04-d158-4bfb-8750-bfb724605cdd","acronym":"P30CA016672","url":"https://clinicaltrials.gov/study/NCT03383575","created_at":"2021-01-18T16:41:48.451Z","updated_at":"2025-02-25T14:37:54.258Z","phase":"Phase 2","brief_title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","source_id_and_acronym":"NCT03383575 - P30CA016672","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-10"},{"id":"625a8643-bad7-473d-8b71-3b4bd3eac313","acronym":"MPN-RC 119","url":"https://clinicaltrials.gov/study/NCT04281498","created_at":"2021-01-18T20:47:14.678Z","updated_at":"2025-02-25T14:29:04.725Z","phase":"Phase 2","brief_title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","source_id_and_acronym":"NCT04281498 - MPN-RC 119","lead_sponsor":"John Mascarenhas","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2025-02-04"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"12c4bdec-2faf-43d1-a25f-e666a7565100","acronym":"NCI-2022-02837","url":"https://clinicaltrials.gov/study/NCT05282459","created_at":"2022-03-16T15:54:13.299Z","updated_at":"2025-02-25T14:16:45.662Z","phase":"Phase 1/2","brief_title":"Enasidenib in MDS \u0026Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation","source_id_and_acronym":"NCT05282459 - NCI-2022-02837","lead_sponsor":"Stanford University","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-09-26"},{"id":"bdecc9b3-c8fa-4ac1-b2d7-05e45884f6a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04522895","created_at":"2021-01-18T21:39:54.008Z","updated_at":"2025-02-25T14:29:32.125Z","phase":"Phase 2","brief_title":"IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT","source_id_and_acronym":"NCT04522895","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2024-09-19"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • Idhifa (enasidenib) • idarubicin hydrochloride • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"ab92a282-919a-4023-ac7a-0869d1798034","acronym":"NCI-2021-00893","url":"https://clinicaltrials.gov/study/NCT04774393","created_at":"2021-03-01T14:52:29.975Z","updated_at":"2024-07-02T16:34:59.147Z","phase":"Phase 1/2","brief_title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04774393 - NCI-2021-00893","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-06-04"},{"id":"66937713-e1c8-4e82-bb66-47047e56b479","acronym":"IDHENTIFY","url":"https://clinicaltrials.gov/study/NCT02577406","created_at":"2021-03-25T18:30:43.571Z","updated_at":"2024-07-02T16:35:06.839Z","phase":"Phase 3","brief_title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","source_id_and_acronym":"NCT02577406 - IDHENTIFY","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 319","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/25/2024","study_completion_date":" 03/25/2024","last_update_posted":"2024-04-30"},{"id":"a900c0e2-07be-4505-9cb0-81a8c6101da5","acronym":"IDEAL Study","url":"https://clinicaltrials.gov/study/NCT03744390","created_at":"2021-01-18T18:20:21.184Z","updated_at":"2024-07-02T16:35:08.558Z","phase":"Phase 2","brief_title":"IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome","source_id_and_acronym":"NCT03744390 - IDEAL Study","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 04/02/2019","start_date":" 04/02/2019","primary_txt":" Primary completion: 02/18/2023","primary_completion_date":" 02/18/2023","study_txt":" Completion: 03/18/2026","study_completion_date":" 03/18/2026","last_update_posted":"2024-04-19"},{"id":"0c2abf24-2704-4d9a-bda5-5112c23b6af6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03515512","created_at":"2021-01-18T17:18:10.487Z","updated_at":"2025-02-25T14:26:53.670Z","phase":"Phase 1","brief_title":"IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT03515512","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH2 • HLA-B","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 07/17/2018","start_date":" 07/17/2018","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 02/13/2023","study_completion_date":" 02/13/2023","last_update_posted":"2024-03-08"},{"id":"259e072d-8792-4679-9b6b-60d1a376f946","acronym":"I-DATA","url":"https://clinicaltrials.gov/study/NCT05401097","created_at":"2022-06-02T16:58:56.588Z","updated_at":"2024-07-02T16:35:16.613Z","phase":"Phase 2","brief_title":"IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)","source_id_and_acronym":"NCT05401097 - I-DATA","lead_sponsor":"Alice Mims","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-03-04"},{"id":"11040b56-b83a-40c8-b335-611302ea384f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03720366","created_at":"2021-01-18T18:14:03.989Z","updated_at":"2024-07-02T16:35:17.394Z","phase":"Phase 1","brief_title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","source_id_and_acronym":"NCT03720366","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib) • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2024-02-28"},{"id":"ab958479-bd13-4a73-bd48-32331d41cc33","acronym":"NCI-2018-01919","url":"https://clinicaltrials.gov/study/NCT03683433","created_at":"2021-01-18T18:03:37.347Z","updated_at":"2024-07-02T16:35:18.098Z","phase":"Phase 2","brief_title":"Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation","source_id_and_acronym":"NCT03683433 - NCI-2018-01919","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 09/20/2025","primary_completion_date":" 09/20/2025","study_txt":" Completion: 09/20/2025","study_completion_date":" 09/20/2025","last_update_posted":"2024-02-22"},{"id":"98b146c5-bd25-418a-a86a-b48aaa091bb5","acronym":"AG-221-C-001","url":"https://clinicaltrials.gov/study/NCT01915498","created_at":"2021-01-17T17:36:57.841Z","updated_at":"2024-07-02T16:35:19.804Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation","source_id_and_acronym":"NCT01915498 - AG-221-C-001","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 345","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 07/25/2019","primary_completion_date":" 07/25/2019","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-02-12"},{"id":"04cc697b-a936-4795-aed4-1231c763328e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441514","created_at":"2022-07-01T20:56:41.287Z","updated_at":"2024-07-02T16:35:25.985Z","phase":"Phase 1","brief_title":"Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05441514","lead_sponsor":"City of Hope Medical Center","biomarkers":" KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172","tags":["KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2023-12-18"},{"id":"19c4df63-c1d0-4fe1-a179-ba050e9a7b85","acronym":"","url":"https://clinicaltrials.gov/study/NCT04955938","created_at":"2021-07-09T12:57:16.797Z","updated_at":"2024-07-02T16:35:49.331Z","phase":"Phase 1","brief_title":"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","source_id_and_acronym":"NCT04955938","lead_sponsor":"University of Chicago","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inrebic (fedratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-04-28"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"fecf6843-8422-4be0-ad2d-bbf921311b94","acronym":"HOVON150AML","url":"https://clinicaltrials.gov/study/NCT03839771","created_at":"2021-01-18T18:57:21.726Z","updated_at":"2024-07-02T16:36:24.976Z","phase":"Phase 3","brief_title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","source_id_and_acronym":"NCT03839771 - HOVON150AML","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" FLT3 • IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation","tags":["FLT3 • IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 968","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2033","study_completion_date":" 03/01/2033","last_update_posted":"2021-09-01"},{"id":"cddda541-8e3f-4ed2-890c-7a3709f68a02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03881735","created_at":"2021-01-18T19:08:06.492Z","updated_at":"2025-02-25T14:28:14.150Z","phase":"Phase 2","brief_title":"Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation","source_id_and_acronym":"NCT03881735","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/02/2019","start_date":" 12/02/2019","primary_txt":" Primary completion: 11/19/2021","primary_completion_date":" 11/19/2021","study_txt":" Completion: 11/19/2022","study_completion_date":" 11/19/2022","last_update_posted":"2021-03-10"},{"id":"ec969d34-99e2-44dd-a268-74c386650639","acronym":"","url":"https://clinicaltrials.gov/study/NCT02273739","created_at":"2021-01-18T10:41:52.200Z","updated_at":"2024-07-02T16:36:34.196Z","phase":"Phase 1/2","brief_title":"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation","source_id_and_acronym":"NCT02273739","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 12/08/2014","start_date":" 12/08/2014","primary_txt":" Primary completion: 06/03/2016","primary_completion_date":" 06/03/2016","study_txt":" Completion: 06/03/2016","study_completion_date":" 06/03/2016","last_update_posted":"2021-02-23"}]